(NASDAQ: ALMS) Alumis's forecast annual revenue growth rate of 155.8% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.84%.
Alumis's revenue in 2026 is $8,402,000.On average, 13 Wall Street analysts forecast ALMS's revenue for 2026 to be $1,140,033,285, with the lowest ALMS revenue forecast at $0, and the highest ALMS revenue forecast at $2,677,331,580. On average, 12 Wall Street analysts forecast ALMS's revenue for 2027 to be $3,053,687,905, with the lowest ALMS revenue forecast at $0, and the highest ALMS revenue forecast at $9,384,047,188.
In 2028, ALMS is forecast to generate $21,440,326,277 in revenue, with the lowest revenue forecast at $10,407,680,295 and the highest revenue forecast at $41,364,772,911.